CoImmune, Inc. Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients DURHAM, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. announced today that the FDA approved its investigational new drug application (IND) and that it is cleared to move forward with a...

CoImmune Inc., a US-based clinical-stage biotech, and Formula Pharmaceutical Inc. agree to merge in an all-stock transaction DURHAM, N.C., Jan. 15, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. and Formula Pharmaceuticals, Inc. announced today the merger between the two companies, bringing together two therapeutic...